UNITED STATES
                      SECURITIES AND EXCHANGE COMMISSION
                            Washington, D.C. 20549

                                   FORM 8-K


                                CURRENT REPORT

  Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934


Date of Report (Date of earliest event reported):      April 28, 2005


                        REGENERON PHARMACEUTICALS, INC.
            ------------------------------------------------------
            (Exact name of registrant as specified in its charter)


         New York                      000-19034                133444607
         --------                      ---------                ---------
(State or other jurisdiction    (Commission File Number)    (I.R.S. Employer
 of incorporation)                                        Identification Number)


          777 Old Saw Mill River Road, Tarrytown, New York    10591-6707
          --------------------------------------------------------------
              (Address of principal executive offices)        (Zip Code)


                                (914) 347-7000
                                --------------
             (Registrant's telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of registrant under any of the
following provisions:

[ ]     Written communications pursuant to Rule 425 under the Securities Act
        (17 CFR 230.425)

[ ]     Soliciting material pursuant to Rule 14a-12 under the Exchange Act
        (17 CFR 240.14a-12)

[ ]     Pre-commencement communications pursuant to Rule 14d-2(b) under the
        Exchange Act (17 CFR 240.14d-2(b))

[ ]     Pre-commencement communications pursuant to Rule 13e-4(c) under the
        Exchange Act (17 CFR 240.13e-4(c))

<PAGE>

Item 2.02    Results of Operations and Financial Condition

             On April 28, 2005, Regeneron Pharmaceuticals, Inc. announced its
             financial and operating results for the quarter ended March 31,
             2005. A copy of the news release is attached hereto as Exhibit
             99(a) and is incorporated herein by reference.

             Effective January 1, 2005, Regeneron began recognizing non-cash
             compensation expense related to employee stock option awards
             (Stock Option Expense) in operating expenses in accordance with
             Statement of Financial Accounting Standards No. 123 (SFAS No.
             123). Prior to the adoption of SFAS No. 123, compensation expense
             related to employee stock options was not reflected in operating
             expenses and prior period operating results have not been
             restated.

             The news release includes certain financial measures that are
             calculated in a manner different from generally accepted
             accounting principles (GAAP) and are considered non-GAAP
             financial measures under United States Securities and Exchange
             Commission rules. Non-GAAP financial measures for the three
             months ended March 31, 2005 included in the news release are: (1)
             pro forma net income and pro forma net income per share (basic
             and diluted), exclusive of Stock Option Expense and (2) research
             and development expenses, general and administrative expenses,
             and contract manufacturing expenses, all exclusive of Stock
             Option Expense. Our management does not intend that the
             presentation of non-GAAP financial measures be considered in
             isolation or as a substitute for results prepared in accordance
             with GAAP.

             Our management believes that the non-GAAP financial measures
             described above present helpful information to investors and
             other users of Regeneron's financial statements by providing
             greater transparency about the nature of and trends in our
             operating expenses and net income and a more useful basis for
             comparing our operating results in the first quarters of 2005 and
             2004. In addition, Regeneron's management uses non-GAAP financial
             measures which exclude Stock Option Expense internally for
             operating, budgeting, and financial planning purposes. The news
             release includes tables which provide a reconciliation of the
             differences between these non-GAAP financial measures and the
             most directly comparable financial measures calculated and
             presented in accordance with GAAP in the news release.

<PAGE>

Item 9.01    Financial Statements and Exhibits

             (c) Exhibits

                 99(a)  Press Release of Regeneron Pharmaceuticals,
                        Inc. dated April 28, 2005.


         Pursuant to the requirements of the Securities and Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.


                                              REGENERON PHARMACEUTICALS, INC.


Dated: April 28, 2005                         By: /s/ Stuart Kolinski
                                                  ----------------------------
                                                  Stuart Kolinski
                                                  Vice President and General
                                                  Counsel

<PAGE>


                                 Exhibit Index

Number        Description
------        -----------

99(a)         Press Release of Regeneron Pharmaceuticals, Inc. dated
              April 28, 2005.
[{"type": "8-K", "sequence": "1", "filename": "bos338493.txt", "description": "FORM 8-K", "secsgml_size_bytes": 5782}]
{"company-data": {"conformed-name": "REGENERON PHARMACEUTICALS INC", "cik": "0000872589", "assigned-sic": "2834", "irs-number": "133444607", "state-of-incorporation": "NY", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-19034", "film-number": "05780972"}, "business-address": {"street1": "777 OLD SAW MILL RIVER RD", "city": "TARRYTOWN", "state": "NY", "zip": "10591-6707", "phone": "9143477000"}}
UNITED STATES
                      SECURITIES AND EXCHANGE COMMISSION
                            Washington, D.C. 20549

                                   FORM 8-K

                                CURRENT REPORT

  Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934

Date of Report (Date of earliest event reported):      April 28, 2005

                        REGENERON PHARMACEUTICALS, INC.
            ------------------------------------------------------
            (Exact name of registrant as specified in its charter)

         New York                      000-19034                133444607
         --------                      ---------                ---------
(State or other jurisdiction    (Commission File Number)    (I.R.S. Employer
 of incorporation)                                        Identification Number)

          777 Old Saw Mill River Road, Tarrytown, New York    10591-6707
          --------------------------------------------------------------
              (Address of principal executive offices)        (Zip Code)

                                (914) 347-7000
                                --------------
             (Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of registrant under any of the
following provisions:

[ ]     Written communications pursuant to Rule 425 under the Securities Act
        (17 CFR 230.425)

[ ]     Soliciting material pursuant to Rule 14a-12 under the Exchange Act
        (17 CFR 240.14a-12)

[ ]     Pre-commencement communications pursuant to Rule 14d-2(b) under the
        Exchange Act (17 CFR 240.14d-2(b))

[ ]     Pre-commencement communications pursuant to Rule 13e-4(c) under the
        Exchange Act (17 CFR 240.13e-4(c))
Item 2.02    Results of Operations and Financial Condition

             On April 28, 2005, Regeneron Pharmaceuticals, Inc. announced its
             financial and operating results for the quarter ended March 31,
             2005. A copy of the news release is attached hereto as Exhibit
             99(a) and is incorporated herein by reference.

             Effective January 1, 2005, Regeneron began recognizing non-cash
             compensation expense related to employee stock option awards
             (Stock Option Expense) in operating expenses in accordance with
             Statement of Financial Accounting Standards No. 123 (SFAS No.
             123). Prior to the adoption of SFAS No. 123, compensation expense
             related to employee stock options was not reflected in operating
             expenses and prior period operating results have not been
             restated.

             The news release includes certain financial measures that are
             calculated in a manner different from generally accepted
             accounting principles (GAAP) and are considered non-GAAP
             financial measures under United States Securities and Exchange
             Commission rules. Non-GAAP financial measures for the three
             months ended March 31, 2005 included in the news release are: (1)
             pro forma net income and pro forma net income per share (basic
             and diluted), exclusive of Stock Option Expense and (2) research
             and development expenses, general and administrative expenses,
             and contract manufacturing expenses, all exclusive of Stock
             Option Expense. Our management does not intend that the
             presentation of non-GAAP financial measures be considered in
             isolation or as a substitute for results prepared in accordance
             with GAAP.

             Our management believes that the non-GAAP financial measures
             described above present helpful information to investors and
             other users of Regeneron's financial statements by providing
             greater transparency about the nature of and trends in our
             operating expenses and net income and a more useful basis for
             comparing our operating results in the first quarters of 2005 and
             2004. In addition, Regeneron's management uses non-GAAP financial
             measures which exclude Stock Option Expense internally for
             operating, budgeting, and financial planning purposes. The news
             release includes tables which provide a reconciliation of the
             differences between these non-GAAP financial measures and the
             most directly comparable financial measures calculated and
             presented in accordance with GAAP in the news release.
Item 9.01    Financial Statements and Exhibits

             (c) Exhibits

                 99(a)  Press Release of Regeneron Pharmaceuticals,
                        Inc. dated April 28, 2005.

         Pursuant to the requirements of the Securities and Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                                              REGENERON PHARMACEUTICALS, INC.

Dated: April 28, 2005                         By: /s/ Stuart Kolinski
                                                  ----------------------------
                                                  Stuart Kolinski
                                                  Vice President and General
                                                  Counsel
Exhibit Index

Number        Description
------        -----------

99(a)         Press Release of Regeneron Pharmaceuticals, Inc. dated
              April 28, 2005.